Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes

MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI™ (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or … Read More

Not-for-profit sector turn to staff cuts amid slump in revenue

Toronto Star By Jason Miller, Staff Reporter Fri., April 17, 2020 It has been a tough month for charitable organizations, as agencies across the sector, which rely heavily on donations, collectively shed hundreds of jobs and are bracing for the loss of millions in revenue. Several organizations have announced major reductions in their workforce, as they restructure their bottom line, … Read More